Yahoo!, WebMD sign search and ad agreement

Share this article:

Online juggernauts in the consumer space, Yahoo! and WebMD announced today that they have inked an exclusive multi-year search and advertising distribution agreement. Financial terms of the deal were not disclosed.

Under the pact, Yahoo! will power search-based and image-heavy display to WebMD consumer advertising sites, which include WebMD health, MedicineNet, eMedicine Health and RxList. WebMD will also be able to show ads sold by its own sales force to visitors of its sites who later go to Yahoo! sites, the companies said.

“This strategic agreement dramatically extends WebMD's ability to uniquely reach health-involved consumers across the breadth of both WebMD and Yahoo! properties,” said WebMD president and CEO Wayne Gattinella, in a statement.

Todd Teresi, SVP of the Yahoo! Publisher Network, added, “This agreement ushers in a new era of collaboration and value creation for marketers seeking qualified audiences, consumers demanding relevant experiences and for our collective organizations as we look to build upon our unique strengths.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...